BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their ...
The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.
Uğur Şahin and Özlem Türeci, a Turkish husband-and-wife team, became unlikely celebrities during the pandemic for their world ...
BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.
The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...
The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.